Alteration in protein interactions with proinsulin and insulin in type 2 diabetes

2 型糖尿病中蛋白质与胰岛素原和胰岛素相互作用的改变

基本信息

项目摘要

DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) is disease epidemic caused by a failure of beta cells to produce sufficient insulin to maintain euglycemia. As a consequence of obesity, insulin resistance develops that pressures the beta cell to produce elevated levels of insulin. Although beta cells have some capacity to compensate by increasing insulin production, a majority of individuals with insulin resistance develop beta cell failure and lose beta cell mass. Unfortunately the mechanism(s) leading to beta cell failure is not understood. We hypothesize that the fundamental cause of beta cell failure in T2D is an inability of the beta cell to fold pro-insulin within the endoplasmic reticulum (ER). To test this central cause of beta cell failure, we have brought together a team of established investigators to use state-of-the-art proteomics to identify the early changes within the secretory pathway that lead to beta cell demise. To accomplish this goal we propose three specific aims (SA). SA 1: To develop sensitive methods to quantify the percentage of folded versus misfolded pro-insulin in beta cells. SA 2: To establish procedures to quantitatively define the entire spectrum of proteins which interact with pro-insulin and insulin within the secretory pathway. SA 3: To devise organelle isolation and quantitative proteomics to map all the proteins within the ER, the Golgi network, and secretory granules of beta cells. To accomplish these aims we will function as a team to establish a novel platform to elucidate the proteomic organization of the beta cell secretory pathway to identify all the factors that contribute to insulin biogenesis. In the future, this proteomic approach will be applied to identify early prognostic markers that lead to beta cell failure and provide a foundation to evaluate new therapeutic modalities for T2D. RELEVANCE (See instructions): Type 2 diabetes (T2D) is an epidemic that results from an inability of beta cells to produce insulin. Recent findings support the notion that pro-insulin misfolding within the endoplasmic reticulum may be an initial event leading to beta cell failure. We propose to develop technologies to identify the protein network that promotes pro-insulin folding that may lead to future diagnostics and therapeutics for T2D.
描述(由申请人提供):2型糖尿病(T2D)是由β细胞无法产生足够的胰岛素以维持正常血糖引起的流行病。由于肥胖,胰岛素抵抗发展,迫使β细胞产生升高的胰岛素水平。虽然β细胞具有通过增加胰岛素产生来补偿的能力,但大多数具有胰岛素抵抗的个体发展为β细胞衰竭并失去β细胞质量。不幸的是,导致β细胞衰竭的机制尚不清楚。我们假设T2D中β细胞衰竭的根本原因是β细胞不能在内质网(ER)内折叠胰岛素原。为了测试β细胞衰竭的这一核心原因,我们召集了一个由研究人员组成的团队,使用最先进的蛋白质组学来确定导致β细胞死亡的分泌途径中的早期变化。为了实现这一目标,我们提出了三个具体目标(SA)。SA 1:开发灵敏的方法来定量β细胞中折叠与错误折叠胰岛素原的百分比。SA 2:建立定量确定分泌途径中与胰岛素原和胰岛素相互作用的整个蛋白质谱的程序。SA 3:设计细胞器分离和定量蛋白质组学,以绘制ER、高尔基体网络和β细胞分泌颗粒内的所有蛋白质。为了实现这些目标,我们将作为一个团队建立一个新的平台来阐明β细胞分泌途径的蛋白质组学组织,以识别有助于胰岛素生物合成的所有因素。在未来,这种蛋白质组学方法将被应用于识别导致β细胞衰竭的早期预后标志物,并为评估T2D的新治疗方式提供基础。相关性(见说明):2型糖尿病(T2D)是一种流行病,由于β细胞无法产生胰岛素。最近的研究结果支持这样的观点,即胰岛素原在内质网内的错误折叠可能是导致β细胞衰竭的初始事件。我们建议开发技术来识别促进胰岛素原折叠的蛋白质网络,这可能导致未来的T2D诊断和治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RANDAL J. KAUFMAN其他文献

RANDAL J. KAUFMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RANDAL J. KAUFMAN', 18)}}的其他基金

Acquisition of Zeiss LSM980 with Airyscan 2, a super-resolution point scanning confocal microscope
购买 Zeiss LSM980 和 Airyscan 2(超分辨率点扫描共焦显微镜)
  • 批准号:
    10632893
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
Overcoming FVIII protein misfolding and cell toxicity
克服 FVIII 蛋白错误折叠和细胞毒性
  • 批准号:
    10560541
  • 财政年份:
    2022
  • 资助金额:
    $ 51.76万
  • 项目类别:
Overcoming FVIII protein misfolding and cell toxicity
克服 FVIII 蛋白错误折叠和细胞毒性
  • 批准号:
    10333189
  • 财政年份:
    2022
  • 资助金额:
    $ 51.76万
  • 项目类别:
Mechanism of ER protein misfolding-induced mitochondrial dysfunction
ER蛋白错误折叠导致线粒体功能障碍的机制
  • 批准号:
    9448713
  • 财政年份:
    2017
  • 资助金额:
    $ 51.76万
  • 项目类别:
Mechanism of ER Protein Misfolding-Induced Mitochondrial Dysfunction
ER蛋白错误折叠引起线粒体功能障碍的机制
  • 批准号:
    9750668
  • 财政年份:
    2017
  • 资助金额:
    $ 51.76万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9914228
  • 财政年份:
    2016
  • 资助金额:
    $ 51.76万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9113989
  • 财政年份:
    2016
  • 资助金额:
    $ 51.76万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9267948
  • 财政年份:
    2016
  • 资助金额:
    $ 51.76万
  • 项目类别:
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
IRE1a-XBP1-PDI1 在肝脂质代谢中的稳态作用
  • 批准号:
    8888815
  • 财政年份:
    2015
  • 资助金额:
    $ 51.76万
  • 项目类别:
eIF2a phosphorylation as a novel druggable target in CRPC
eIF2a 磷酸化作为 CRPC 的新型药物靶点
  • 批准号:
    8805370
  • 财政年份:
    2015
  • 资助金额:
    $ 51.76万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 51.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了